HK$12.04
2.75%
Hong Kong, Oct 08, 01:15 pm HKT. Market open.
ISIN
KYG1996C1006
Symbol
2171

Carsgen Therapeutics Holding Stock price

HK$12.38
-0.88 6.64% 1M
-6.01 32.68% 6M
-2.47 16.63% YTD
-9.38 43.11% 1Y
+3.76 43.62% 3Y
-32.97 72.70% 5Y
-17.62 58.73% 10Y
-17.62 58.73% 20Y
Hong Kong, Closing price Wed, Oct 07 2026
-0.62 4.77%
ISIN
KYG1996C1006
Symbol
2171
Industry

Is Carsgen Therapeutics Holding a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,113 stocks worldwide.

Key metrics

Basic
Market capitalization
HK$7.7b
Enterprise Value
HK$6.3b
Net debt
positive
Cash
HK$1.6b
Shares outstanding
594.7m
Valuation
P/E
negative
P/S | estimate
48.3 | 21.8
EV/Sales | estimate
39.2 | 17.7
EV/FCF | ex SBC
- | -
P/B
6.0
Financial Health
Equity Ratio
60.6%
Return on Equity
-12.5%
ROCE
-16.4%
ROIC
-
Debt/Equity
0.1
Financials
Revenue | estimate
HK$159.9m | HK$353.7m
EBITDA
HK$-228.5m
EBIT
HK$-263.2m
Net Income
HK$-104.4m
Free Cash Flow | ex SBC
- | -
Growth
Revenue | estimate
62.6% | 140.5%
EBITDA
62.3%
EBIT
60.2%
Net Income
82.9%
Free Cash Flow
-
Margin
Gross
67.8%
EBITDA
-142.9%
EBIT
-164.6%
Net
-65.3%
Free Cash Flow | ex SBC
- | -
More
EPS
HK$-0.2
FCF per Share
-
Short interest
-
Employees
362
Rev per Employee
HK$410.0k

Carsgen Therapeutics Holding Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Carsgen Therapeutics Holding forecast:

7x Buy
78%
1x Hold
11%
1x Sell
11%

Analyst Opinions

9 Analysts have issued a Carsgen Therapeutics Holding forecast:

Buy
78%
Hold
11%
Sell
11%

Financial data from Carsgen Therapeutics Holding

Jun '26
+/-
%
160 160
63% 63%
100%
- Direct Costs 52 52
6% 6%
32%
108 108
118% 118%
68%
- Selling and Administrative Expenses 87 87
25% 25%
54%
- Research and Development Expense 258 258
31% 31%
161%
-229 -229
62% 62%
-143%
- Depreciation and Amortization 35 35
36% 36%
22%
EBIT (Operating Income) EBIT -263 -263
60% 60%
-165%
Net Profit -104 -104
83% 83%
-65%

In millions HKD.

Don't miss a Thing! We will send you all news about Carsgen Therapeutics Holding directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

CARsgen Therapeutics Holdings Ltd. is a clinical-stage biopharmaceutical company, which engages in discovering, researching, and developing cell therapies. The company is headquartered in Shanghai, Shanghai and currently employs 468 full-time employees. The company went IPO on 2021-06-18. The Company’s main business is engaged in developing chimeric antigen receptor T cell (CAR T) -cell therapies to address clinical needs including but not limited to hematologic malignancies solid tumors and autoimmune diseases. The Company’s main products include zevor-cel (zevorcabtagene autoleucel), satricabtagene autoleucel and allogeneic CAR T-cell products. The firm conducts its business in the domestic and overseas markets.

Head office Cayman Islands
CEO Mr. Li
Employees 362
Website www.carsgen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today